Legal & General Group
BPMC

Legal & General Group’s Blueprint Medicines BPMC Stock Holding History

Legal & General Group’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-99,224
Closed -$12.7M – 3413
2025
Q2 		$12.7M Buy
99,224
+3,558
+4% +$370K ﹤0.01% 1070
2025
Q1 		$8.47M Buy
95,666
+1,150
+1% +$112K ﹤0.01% 1225
2024
Q4 		$8.24M Buy
94,516
+3,485
+4% +$319K ﹤0.01% 1296
2024
Q3 		$8.42M Buy
91,031
+3,816
+4% +$379K ﹤0.01% 1274
2024
Q2 		$9.4M Buy
87,215
+27,716
+47% +$2.77M ﹤0.01% 1161
2024
Q1 		$5.64M Buy
59,499
+535
+0.9% +$45.9K ﹤0.01% 1452
2023
Q4 		$5.44M Buy
58,964
+508
+0.9% +$32.9K ﹤0.01% 1464
2023
Q3 		$2.94M Buy
58,456
+592
+1% +$31.6K ﹤0.01% 1724
2023
Q2 		$3.66M Sell
57,864
-399
-0.7% -$21.7K ﹤0.01% 1627
2023
Q1 		$2.62M Buy
58,263
+4,824
+9% +$217K ﹤0.01% 1753
2022
Q4 		$2.34M Sell
53,439
-32
-0.1% -$1.53K ﹤0.01% 1808
2022
Q3 		$3.52M Sell
53,471
-1,237
-2% -$79.5K ﹤0.01% 1557
2022
Q2 		$2.76M Buy
54,708
+1,344
+3% +$78.7K ﹤0.01% 1721
2022
Q1 		$3.41M Buy
53,364
+430
+0.8% +$30.9K ﹤0.01% 1736
2021
Q4 		$5.67M Buy
52,934
+656
+1% +$68.6K ﹤0.01% 1504
2021
Q3 		$5.37M Buy
52,278
+10,807
+26% +$1.01M ﹤0.01% 1508
2021
Q2 		$3.65M Buy
41,471
+5,932
+17% +$544K ﹤0.01% 1705
2021
Q1 		$3.46M Buy
35,539
+627
+2% +$62.6K ﹤0.01% 1751
2020
Q4 		$3.92M Buy
34,912
+1,115
+3% +$118K ﹤0.01% 1587
2020
Q3 		$3.13M Sell
33,797
-2,240
-6% -$172K ﹤0.01% 1569
2020
Q2 		$2.81M Buy
36,037
+590
+2% +$39.9K ﹤0.01% 1582
2020
Q1 		$2.07M Buy
35,447
+2,545
+8% +$164K ﹤0.01% 1567
2019
Q4 		$2.64M Buy
32,902
+6,237
+23% +$467K ﹤0.01% 1662
2019
Q3 		$1.96M Buy
26,665
+3,458
+15% +$299K ﹤0.01% 1724
2019
Q2 		$2.19M Buy
23,207
+3,007
+15% +$248K ﹤0.01% 1658
2019
Q1 		$1.62M Buy
20,200
+3,565
+21% +$263K ﹤0.01% 1777
2018
Q4 		$897K Buy
16,635
+995
+6% +$60.5K ﹤0.01% 1938
2018
Q3 		$1.22M Hold
15,640
– – ﹤0.01% 1887
2018
Q2 		$992K Sell
15,640
-1,266
-7% -$101K ﹤0.01% 1928
2018
Q1 		$1.55M Sell
16,906
-1,036
-6% -$89.3K ﹤0.01% 1729
2017
Q4 		$1.36M Buy
17,942
+2,040
+13% +$144K ﹤0.01% 1775
2017
Q3 		$1.11M Buy
15,902
+6,208
+64% +$332K ﹤0.01% 1828
2017
Q2 		$490K Buy
9,694
+3,810
+65% +$162K ﹤0.01% 2050
2017
Q1 		$235K Buy
5,884
+1,419
+32% +$50.8K ﹤0.01% 2206
2016
Q4 		$125K Buy
4,465
+1,341
+43% +$40.4K ﹤0.01% 2425
2016
Q3 		$87K Sell
3,124
-194
-6% -$4.82K ﹤0.01% 2275
2016
Q2 		$63K Buy
+3,318
New +$60.3K ﹤0.01% 2345

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Legal & General Group's BPMC Position: Q3 2025 in Review

Legal & General Group sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 99,224 shares — an estimated $12.7M sold.

Legal & General Group first reported a position in BPMC in Q2 2016 and held it in 37 quarters. The position peaked at $12.7M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Legal & General Group reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Legal & General Group sold 99,224 Blueprint Medicines shares in Q3 2025, an estimated $12.7M.
  • Legal & General Group first reported a position in Blueprint Medicines in Q2 2016 and held it in 37 quarters.
  • Legal & General Group's Blueprint Medicines position peaked at $12.7M in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Legal & General Group's 13F filing for Q3 2025, filed 13 Nov 2025.